Serum paraoxonase

KAPLAN M and AVIRAM M (1999) Oxidized low density lipoprotein atherogenic and proinflammatoiy characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase Clinical Chemistry Laboratory Medicine 37,111-9,1. 

K. N. Gan, A. Smolen, H. W. Eckerson, B. N. La Du, Purification of Human Serum Paraoxonase/Arylesterase. Evidence for One Esterase Catalyzing Both Activities , Drug Metab. Dispos. 1991,19, 100-106. 

N. La Du, The Human Serum Paraoxonase/Arylesterase Gene (PON1) Is One Member of a Multigene Family , Genomics 1996, 33, 498-507. 

C. L. Kuo, B. N. La Du, Comparison of Purified Human and Rabbit Serum Paraoxonases , Drug Metab. Dispos. 1995, 23, 935-944 C. L. Kuo, B. N. La Du, Calcium Binding by Human and Rabbit Serum Paraoxonases. Structural Stability and Enzymatic Activity , Drug Metab. Dispos. 1998, 26, 653-660. 

Of great interest is the recent finding that human serum paraoxonase (EC 3.1.8.1, which belongs to the class of A-esterases), is very active in hydrolyzing a range of four-, five-, six-, and seven-membered lactones [167], Some cyclic carbonates (see Sect. 7.6.3) were also substrates. 

S. Billecke, D. Draganov, R. Councell, P. Stetson, C. Watson, C. Hsu, B. N. La Du, Human Serum Paraoxonase (PON1) Isozymes Q and R Hydrolyze Lactones and Cyclic Carbonate Esters , Drug Metab. Dispos. 2000, 28, 1335- 1347. 

T. L. Diepgen, M. Geldmacher-von Mallinckrodt, Interethnic Differences in the Detoxification of Organophosphates The Human Serum Paraoxonase Polymorphism , Arch. Toxicol. 1986, Suppl. 9, 154-158. 

Gan, K.N., et al. 1991. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 19 100. 

Mackness B, Mackness MI, Arrol S, Turkie W, Durrington PN. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEB Lett 1998 423 57-60. 

Kiyici, A. Okudan, N. Gokbel, H. Belviranli, M. 2010. The effect of grape seed extracts on serum paraoxonase activities in streptozotocin-induced diabetic rats. J. Med. Food 13 725-728. 

Li, W.F., Costa, L.G., Furlong, C.E. (1993). Serum paraoxonase status a major factor in determining resistance to organo-phosphates. J. Toxicol. Environ. Health 40 337 6. 

Josse, D., Xie, W., Masson, P., Lockridge, O. (1999a). Human serum paraoxonase (PONl) identification of essential amino acid residues by group-selective labelling and site-directed mutagenesis. Chem. Biol. Interact. 119-20 71-8. 

Khersonsky, O., Tawfik, D.S. (2006). The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J. Biol. Chem. 281 7649-56. 

Mackness, B., Durrington, P.N., Mackness, M.I. (1998a). Human serum paraoxonase. Gen. Pharmacol. 31 329-36. 

Pasca, S.P., Nemes, B., Vlase, L., Gagyi, C.E., Dronca, E., Miu, A.C., Dronca, M. (2006). High levels of homocysteine and low serum paraoxonase 1 arylesterase activity in children with autism. Life Sci. 78 2244-8. 

Primo-Parmo, S.L., Sorenson, R.C., Teiher, J., La Du, B.N. (1996). The human serum paraoxonase/arylesterase gene (PONl) is one member of a multigene family. Genomics 33 498-507. 

Shih, D.M., Xia, Y.R., Wang, X.P., Miller, E., Castellani, L.W., Suhhanagounder, G., Cheroutre, H., Faull, K.F., Berliner, J.A., Witztum, J.L., Lusis, A.J. (2000). Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J. Biol. Chem. 275 17527-35. 

Yermg, D.T., Josse, D., Nicholson, J.D., Khanal, A., McAndrew, C.W., Bahnson, B.J., Lenz, D.E., Cerasoli, D.M. (2004). Stmctiue/fimction analyses of hiunan serum paraoxonase (HuPONl) mutants designed from a DFPase-lrke homology model. Biochim. Biophys. Acta 1702 67-77. 

Billecke, S., Draganov, D., Counsell, R., Stetson, P., Watson, C., Hsu, C., La Du, B.N. (2000). Human serum paraoxonase (PONl) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab. Dispos. 28 1335-42. 

Davies, H.G., Richter, R.J., Keifer, M., Broomfield, C.A., Sowalla, J., Furlong, C.E. (1996). The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat. Genet. 14 334-6. 

Amitai, G. Gaidukov, L., Adani, R., Yishay, S., Yacov, G., Kushnir, M., Teitlboim, S., Lindenbaum, M., Bel, P., Khersonsky, O., Tawfik, D.S., Meshulam, H. (2006). Enhanced stereoselective hydrolysis of toxic organophosphates by directly evolved variants of mammalian serum paraoxonase. FEBSJ. 273 1906-19. 

Costa, L.G., Richter, R.J., Murphy, S.D., Omenn, G.S., Moml-sky, A.G., Furlong, C.E. (1987). Species differences in serum paraoxonase correlate with sensitivity to paraoxon toxicity. In Toxicology of Pesticides Experimental Clinical and Regulatory Perspectives (L.G. Costa, C.L. Galli, S.D. Murphy, eds), pp. 263-6. Springer-Verlag, Heidelberg. 

---